ISRCTN81058036已完成不适用

Randomised multicentric controlled clinical trial to compare efficacy of rifabutin-based therapy versus quadruple therapy as second-line treatment in the infection of Helicobacter pylori

Andalusian Digestive Disease Society (Sociedad Andaluza de Patología Digestiva) (Spain)0 个研究点目标入组 206 人开始时间: 2007年4月25日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•Patients in whom Helicobacter pylori infection persisted after a triple therapy treatment were included.

•1. Withheld consent
•2. Had initially been treated by the Test and Treat procedure, or a baseline endoscopy was not obtained
•3. Fulfilment of the treatment regimen and attendance at follow-up appointments could not reasonably be expected
•4. Human Immunodeficiency Virus (HIV) positive status
•5. Active alcoholism
•6. Addiction to drugs
•7. Age less than 18 years or more than 75 years
•8. The suspicion of tuberculous infection
•9. Either because of a positive intradermal reaction to Mantoux and compatible thorax radiography, or if the patient had previously received tuberculostatic treatment, or a known allergy to any of the components of either of the two treatment regimens
•10. Received quadruple therapy as first-line treatment, or any other treatment including bismuth (e.g., ranitidine bismuth citrate), or antibiotics during the previous month
•11. Severe associated diseases:
•a. cardiac insufficiency
•b. respiratory insufficiency
•c. chronic kidney insufficiency
•d. hepatic insufficiency
•e. advanced neoplasic diseases
•12. Pregnant or lactating

发起方

Andalusian Digestive Disease Society (Sociedad Andaluza de Patología Digestiva) (Spain)